Healthy volunteers needed to test new Drug's absorption and food effects
NCT ID NCT07226817
First seen Jun 26, 2026 · Last updated Aug 13, 2026 · Updated 5 times
Summary
This study in 140 healthy adults tests how well different tablet versions of the drug BMS-986435 are absorbed into the body and whether taking it with food changes absorption. Participants will receive one or more doses of the drug in different tablet forms. The goal is to pick the best tablet and understand food effects for future studies.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- BMS-986435 (also called MYK-224)
- What this could lead to
- If successful, this study will help determine the best tablet form and dosing conditions for future trials of BMS-986435.
- What could go wrong
- This is an early Phase 1 study in healthy people, not patients. It only measures drug levels and safety, not whether the drug works for any disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
About 240 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2025
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 60 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria * Participants must have a body weight of ≥ 45 kg and BMI between 18 and 32 kg/m2, inclusive * Participants must be healthy as determined by medical history, physical examination, vital signs, 12-lead electrocardiogram (ECG), clinical laboratory assessments * Participants must have documented left ventricular ejection fraction (LVEF) ≥ 60% and absence of significant cardiac abnormality at screening, as determined by local transthoracic echocardiogram (TTE) assessment * Other protocol-defined Inclusion/Exclusion criteria apply
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy volunteers are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Quotient Miami
RECRUITINGMiami, Florida, 33126, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New sedative candidate goes Head-to-Head with propofol in early human test
- Can a Room-Temperature dairy drink build muscle?
- New injection MWN117 tested for safety in obesity
- Can a new drug avoid the high? soticlestat put to the test
- Liver trouble changes how drugs work: scientists test soticlestat
- Can a hard cycling sprint change a Heart-Calming peptide?